Equities

Sinphar Pharmaceutical Co Ltd

1734:TAI

Sinphar Pharmaceutical Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (TWD)30.45
  • Today's Change-0.05 / -0.16%
  • Shares traded124.08k
  • 1 Year change-0.04%
  • Beta--
Data delayed at least 20 minutes, as of Nov 14 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Sinphar Pharmaceutical Co., Ltd. is principally engaged in the research and development, manufacture and distribution of pharmaceuticals. The Company is also engaged in the sales of functional food products. The Company’s principal products include ointment, gel, cream, hard and soft capsules, sugar-coated tablets, film-coated tablets, suppositories, powders and granules, lozenges, soft candies, oral and topical liquid medicines, injections, dry medicated powers, functional food products, medical equipment and cosmetics. The Company mainly sells its products to hospitals, drug stores, clinics, dealers and distributors. Its primary markets are located in Taiwan and overseas countries.

  • Revenue in TWD (TTM)3.01bn
  • Net income in TWD361.33m
  • Incorporated1977
  • Employees984.00
  • Location
    Sinphar Pharmaceutical Co LtdNo.84Chung Shan Road, Chung Shan VillageDONGSHAN 269TaiwanTWN
  • Phone+886 39581101
  • Fax+886 39580187
  • Websitehttp://www.sinphar.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Phytohealth Corp163.13m-86.82m3.30bn84.00--1.71--20.21-0.4371-0.43710.82139.720.06790.62694.19---5.15-5.66-6.35-7.3139.9247.70-75.82-92.9131.96--0.0088--19.958.6240.67---40.76--
Nang Kuang Pharmaceutical Co Ltd2.09bn110.65m4.35bn552.0039.341.9114.852.081.091.0920.7222.520.5711.898.07--3.026.754.479.6433.1434.775.2812.220.631214.420.158782.7410.816.92-43.6314.4119.5110.76
Sinphar Pharmaceutical Co Ltd3.01bn361.33m5.52bn984.0014.181.649.381.832.152.1517.9318.610.48642.286.06--5.71-0.01477.67-0.020339.0237.4911.74-0.03441.4437.220.359979.703.725.9867.01111.883.3158.49
Cenra Inc8.87bn355.20m5.58bn1.40k31.451.507.960.62921.191.1929.7324.900.70272.225.63--2.833.694.034.9636.7936.564.025.500.7959--0.294352.771.402.50-32.51-2.723.57-8.97
Formosa Pharmaceuticals Inc133.70m-298.43m6.43bn----5.65--48.10-2.22-2.220.99637.540.0803--1.61---17.91-40.34-19.62-44.2186.96---223.16-2,488.28----0.0277--2,270.49--20.75---42.98--
Data as of Nov 14 2024. Currency figures normalised to Sinphar Pharmaceutical Co Ltd's reporting currency: Taiwan Dollar TWD

Institutional shareholders

2.66%Per cent of shares held by top holders
HolderShares% Held
Dimensional Fund Advisors LPas of 03 Oct 20242.32m1.28%
SSgA Funds Management, Inc.as of 03 Oct 20242.26m1.25%
Dimensional Fund Advisors Ltd.as of 31 Aug 2024187.44k0.10%
Arrowstreet Capital LPas of 30 Sep 202424.84k0.01%
DFA Australia Ltd.as of 30 Sep 202421.81k0.01%
American Century Investment Management, Inc.as of 03 Oct 20244.32k0.00%
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.